Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Debra Gazzuolo

Internal Medicine Charlotte, NC Medical Doctor

NPI 1548253347 CMS profile 69473

6115 Park South Dr Ste 100, Charlotte, NC 28210

Open in the dashboard

General payments

$5,406

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Debra Gazzuolo of Charlotte, NC is reported in the CMS Open Payments database as having received $5,406 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $903 44
2024 General $1,085 61
2023 General $930 53
2022 General $771 49
2021 General $731 54
2020 General $439 29
2019 General $546 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Debra Gazzuolo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Debra Gazzuolo were reported at $903. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Debra Gazzuolo Internal Medicine median Middle half National median
2019 $546 $159 $48–$570 $163
2020 $439 $119 $33–$402 $114
2021 $731 $135 $37–$521 $132
2022 $771 $141 $42–$496 $149
2023 $930 $149 $45–$519 $160
2024 $1,085 $154 $47–$537 $164
2025 $903 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $774 51 payments
  2. AbbVie, Inc. $614 45 payments
  3. Pfizer Inc. $405 24 payments
  4. Amgen Inc. $369 23 payments
  5. Lilly USA, LLC $291 18 payments
  6. Novartis Pharmaceuticals Corporation $250 10 payments
  7. AstraZeneca Pharmaceuticals LP $239 16 payments
  8. Sumitomo Pharma America, Inc. $188 9 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $144 9 payments
  10. Amarin Pharma Inc. $138 9 payments
  11. Other $1,994 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,406 326 payments
Products named General payments · program years 2019–2025
  1. Ozempic $498 35 payments
  2. RYBELSUS $389 29 payments
  3. UBRELVY $362 26 payments
  4. Repatha $218 15 payments
  5. COMIRNATY $218 11 payments
  6. PREVNAR 20 $216 11 payments
  7. Otezla $213 15 payments
  8. MOUNJARO $200 12 payments
  9. GEMTESA $188 9 payments
  10. QULIPTA $171 10 payments
  11. Other $4,927 282 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,125

Median for Internal Medicine: 777

Drug cost

$126,520

Median for Internal Medicine: $73,373

Branded share of claims

22.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 16 $18,456
Eliquis Apixaban Brand 22 $16,108
Januvia Sitagliptin Phosphate Brand 14 $14,893
Rybelsus Semaglutide Brand 15 $13,430
Linzess Linaclotide Brand 20 $12,404
Gemtesa Vibegron Brand 16 $10,648
Myrbetriq Mirabegron Brand 21 $10,195
Xarelto Rivaroxaban Brand 14 $7,735
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 13 $4,019
Synthroid Levothyroxine Sodium Brand 35 $3,332

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$45,855

Of which drugs: $14,030

Medicare patients

86

Average age 76

Services billed

1,094

66 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 51%
Osteoporosis 31%
Cancer 20%
Depression 17%
Diabetes 15%
Atrial fibrillation 15%
Ischemic heart disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 30 32 $4,719
Pcv20 vaccine im 90677 Office 16 16 $4,609
Vaccine for influenza for injection into muscle 90653 Office 29 29 $2,373

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $95
$95 16 —
GEMTESA
  • Sumitomo Pharma America, Inc. $87
$87 16 —
UBRELVY
  • AbbVie, Inc. $73
$73 — —
RYBELSUS
  • Novo Nordisk Inc $68
$68 15 —
Ozempic
  • Novo Nordisk Inc $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record